Text Size

An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00067262
First received: August 13, 2003
Last updated: August 2, 2006
Last verified: August 2006
History of Changes

August 13, 2003
August 2, 2006
March 2003
Not Provided
Change from baseline to the final evaluation in Y-MRS score.
Not Provided
Complete list of historical versions of study NCT00067262 on ClinicalTrials.gov Archive Site
  • Vital signs
  • Adverse events
Not Provided
Not Provided
Not Provided
 
An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents

The purpose of this study is to determine the safety and effectiveness of Depakote ER (Divalproex Sodium Extended-Release Tablets) compared to placebo in the treatment of bipolar disorder, manic or mixed type in children and adolescents ages 10-17 years.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Bipolar Disorder
Drug: Divalproex Sodium Extended-Release Tablets
Not Provided
Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, Wozniak P, Vigna NV, Abi-Saab W, Saltarelli M. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):519-32.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
Not Provided
Not Provided

INCLUSION CRITERIA

  • Current primary diagnosis of bipolar I disorder, mania or mixed type
  • Outpatient between 10 and 17 years of age
  • Young Mania Rating Scale score greater than or equal to 20 during screening/washout and at Day 1

EXCLUSION CRITERIA

  • Axis I other than Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Panic Disorder; or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results
  • Current manic episode is drug-induced or secondary to a medical disorder (e.g., anti-depressants, hyperthyroidism)
  • Expected to require hospitalization for the current manic episode
  • Participation in psychotherapy that was started within the past 3 months, or if any significant changes are anticipated
  • Has taken atomoxetine or has taken allowed stimulant medication that has not been stable for at least 3 months prior to Day 1, or a dosage adjustment is expected during the study, or that may worsen mood symptoms
  • Unable to swallow tablets
  • Has received depot psychoactive medication within one inter-injection interval of Day 1
  • Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine, barbiturates, benzodiazepines or amphetamines
  • History of alcohol or substance dependence within past 3 mos. or substance abuse within past month
  • History of failed treatment on adequate Depakote (DR or ER) for a manic episode within past 12 months
  • Has taken Depakote (DR or ER) regularly for the current manic episode
  • Has serious violent, homicidal, or suicidal ideation
Both
10 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00067262
M01-342
Not Provided
Not Provided
Abbott
Not Provided
Study Director: Global Medical Information Abbott
Abbott
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP